Drugs approved by the Food and Drug Administration (FDA) for the treatment of AD, including acetylcholinesterase inhibitors, donepezil, rivastigmine, and galanthamine, can only improve the symptoms of AD patients but cannot slow down or reverse the progress of the disease, resulting in a large number of unmet medical needs (Ayaz et al., 2015). Here, ACHE is linked to Alzheimer disease.